Medical News Today, 29 Oct 2008
Australia-listed, Singapore-based healthcare group, Rockeby biomed Ltd (ASX:RBY), today announced that it has been awarded two grants by the Singaporean Standards, Productivity and Innovation Board (SPRING Singapore) under the Technology Enterprise Commercialisation Scheme (TECS). The first grant of S$250,000 awarded under Proof of Concept (POC) is for the development of a magnetic detection platform for influenza A, including avian flu, while the second grant of S$500,000 is awarded under Proof of Value (POV), to upscale the production of a rapid and sensitive test incorporating fluorescence technology for the field diagnosis of influenza A, including avian flu.
The letters of offer were presented to Dr. Tan Sze Wee, Managing Director and CEO of Rockeby biomed at the TECS award ceremony today.
Read More
